The therapeutic potential of neuronal KCNQ channel modulators
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Neuronal KCNQ (Kv7) channels (KCNQ2-5 or Kv7.2-7.5, disclosed to date) were discovered by virtue of their homology with a known cardiac channel involved in long QT syndrome (KvLQT or KCNQ1, Kv7.1) and first disclosed in 1998. The involvement of KCNQ2 (Kv7.2) and KCNQ3 (Kv7.3) in a benign idiopathic neonatal epilepsy, KCNQ4 (Kv7.4) in a form of congenital deafness, and the discovery that neuronal KCNQ heteromultimers were among the molecular substrates of M-channels, resulted in a high level of interest for potential drug development strategies. A number of small-molecule modulators were quickly identified, including openers or activators such as the antiepileptic drug candidate retigabine and the structurally-related analgesic drug flupirtine (Katadolon trade mark Asta Medica), and a group of KCNQ channel inhibitors/blockers originally developed for cognition enhancement. All of these data have suggested a rich target profile for modulators of neuronal KCNQ channels, including a variety of neuronal hyperexcitability disorders and conditions for openers, such as the epilepsies, acute pain, neuropathic pain, migraine pain and some neurodegenerative and psychiatric disorders. KCNQ blockers could likewise have utility in disorders characterised by neuronal hypoactivity, including cognition enhancement and perhaps disorders of mood. Emerging patent literature suggests significant interest in neuronal KCNQ modulation in the pharmaceutical industry and significant chemical diversity concerning KCNQ modulation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns
Singh, N. A., Charlier, C., Stauffer, D., DuPont, B. R., Leach, R. J., Melis, R., Ronen, G. M., Bjerre, I., Quattlebaum, T., Murphy, J. V., et al. (1998) · Nature Genetics · doi:10.1038/ng0198-25 · Cited by 1,199 · cited 3×
“These epilepsies are the result of loss of function or reduced function channel mutations [4-6].”
BackgroundA Potassium Channel Mutation in Neonatal Human Epilepsy
Biervert, C., Schroeder, B. C., Kubisch, C., Berkovic, S. F., Propping, P., Jentsch, T. J., & Steinlein, O. K. (1998) · Science · doi:10.1126/science.279.5349.403 · Cited by 1,073 · cited 3×
“These epilepsies are the result of loss of function or reduced function channel mutations [4-6].”
BackgroundZhang, H., Craciun, L. C., Mirshahi, T., Rohács, T., Lopes, C. M. B., Jin, T., & Logothetis, D. E. (2003) · Neuron · doi:10.1016/s0896-6273(03)00125-9 · Cited by 523 · cited 2×
“PIP2 activates KCNQ channels directly [63] and is even capable of producing recovery of current in excised patches from HEK293 cells expressing recombinant hKCNQ2/3 after nearly complete rundown (author’s unpublished observations).”
BackgroundPotassium Channels, Proliferation and G1 Progression
Wonderlin, W. F., & Strobl, J. S. (1996) · Journal of Membrane Biology · doi:10.1007/s002329900135 · Cited by 402 · cited 1×
“Of diverse structure, they are involved in the regulation of neurotransmitter and hormone release and smooth muscle contractility, and are a component of the systems regulating other functions from energy availability and hypoxic response to cell growth and differentiation, among many other functions [12-18].”
BackgroundTombaugh, G. C., Rowe, W. B., Chow, A. R., Michael, T. H., & Rose, G. M. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-22-09932.2002 · Cited by 144
Cited by
Pan, Z., Kao, T., Horvath, Z., Lemos, J., Sul, J.-Y., Cranstoun, S. D., Bennett, V., Scherer, S. S., & Cooper, E. C. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.4314-05.2006 · Cited by 585
Gunthorpe, M. J., Large, C. H., & Sankar, R. (2012) · Epilepsia · doi:10.1111/j.1528-1167.2011.03365.x · Cited by 319
Potassium channels and pain: present realities and future opportunities
Ocaña, M., Cendán, C. M., Cobos, E. J., Entrena, J. M., & Baeyens, J. M. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.07.026 · Cited by 265
Vervaeke, K., Gu, N., Agdestein, C., Hu, H., & Storm, J. F. (2006) · The Journal of Physiology · doi:10.1113/jphysiol.2006.111336 · Cited by 135
Targeting Kv7 Potassium Channels for Epilepsy
Perucca, E., & Taglialatela, M. (2025) · CNS Drugs · doi:10.1007/s40263-024-01155-3 · Cited by 43
“3 channels for the treatment of seizure disorders and other indications, such as pain, affective disorders, and overactive bladder syndrome [45, 46, 173–175], a number of novel activators of these channels have recently been described, including SF0034 [176], ZG1732 and ZG2083 [177], RL-81 [178],…”
Metadata
- Authors
- Gribkoff, V. K.
- Venue
- Expert Opinion on Therapeutic Targets
- Publisher
- Informa Healthcare
- Published
- 2003-12
- Volume
- 7
- Issue
- 6
- Pages
- 737-748
- ISSN
- 1472-8222 (ISSN-L)
- 1744-7631
- OpenAlex
- W2134418949
- Cited by
- 81
- References
- 5
- FWCI
- 1.82
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The therapeutic potential of neuronal KCNQ channel modulators. https://app.cochat.ai/papers/10.1517/14728222.7.6.737
- The paper
- Gribkoff, V. K. (2003). The therapeutic potential of neuronal KCNQ channel modulators. Expert Opinion on Therapeutic Targets. https://doi.org/10.1517/14728222.7.6.737
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.